KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Intangibles: 2022-2024

Historic Change in Intangibles for Recursion Pharmaceuticals (RXRX) over the last 1 years, with Dec 2024 value amounting to $350,000.

  • Recursion Pharmaceuticals' Change in Intangibles changed negligibly% to $350,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $3.8 million, marking a year-over-year increase of 321.63%. This contributed to the annual value of $3.4 million for FY2024, which is 461.14% up from last year.
  • According to the latest figures from Q4 2024, Recursion Pharmaceuticals' Change in Intangibles is $350,000, which was down 88.33% from $3.0 million recorded in Q2 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Change in Intangibles peaked at $3.0 million during Q2 2024, and registered a low of $82,000 during Q3 2023.
  • For the 3-year period, Recursion Pharmaceuticals' Change in Intangibles averaged around $707,833, with its median value being $325,000 (2022).
  • Data for Recursion Pharmaceuticals' Change in Intangibles shows a maximum YoY crashed of 72.67% (in 2023) over the last 5 years.
  • Over the past 3 years, Recursion Pharmaceuticals' Change in Intangibles (Quarterly) stood at $300,000 in 2022, then slumped by 72.67% to $350,000 in 2023, then remained steady at $350,000 in 2024.
  • Its last three reported values are $350,000 in Q4 2024, $3.0 million for Q2 2024, and $350,000 during Q4 2023.